Theravance Biopharma (TBPH) FCF Margin Growth (5y) (2018 - 2026)
Analysis
Theravance Biopharma (TBPH) FCF Margin Growth (5y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 35,566.00 |
| Mar 31, 2026 | 91,646.00 |
| Dec 31, 2025 | 40,595.00 |
| Sep 30, 2025 | 40,060.00 |
| Jun 30, 2025 | 116,556.00 |
| Mar 31, 2025 | 56,191.00 |
| Dec 31, 2024 | 2,153.00 |
| Sep 30, 2024 | 32,880.00 |
| Jun 30, 2024 | 5,879.00 |
| Mar 31, 2024 | 153,622.00 |
| Dec 31, 2023 | 33,238.00 |
| Sep 30, 2023 | 38,013.00 |
| Jun 30, 2023 | 17,014.00 |
| Mar 31, 2023 | -68,234.00 |
| Dec 31, 2022 | 13,599.00 |
| Sep 30, 2022 | 129,927.00 |
| Jun 30, 2022 | 116,115.00 |
| Mar 31, 2022 | 143,545.00 |
| Dec 31, 2021 | 19,520.00 |
| Sep 30, 2021 | -47,523.00 |